Metamizol Basi

Metamizole, the active ingredient in Metamizol Basi, is a pyrazolone analgesic presented as an injectable solution for intramuscular or intravenous use. It is employed to manage pain and fever, particularly in postoperative settings and acute care patients.

GNH USA supplies Metamizol Basi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metamizol Basi is used for conditions where rapid analgesic or antipyretic control is required.

- Pain: Provides analgesic relief for moderate to severe acute pain. - Fever: Reduces elevated body temperature in febrile states. - Post‑operative analgesia: Controls pain and fever after surgical procedures.

Metamizol Basi may be associated with a range of adverse reactions.

Common Side Effects: - Injection site pain: Discomfort at the site of administration. - Nausea: Mild to moderate feeling of queasiness. - Dizziness: Transient light‑headedness. - Hypotension: Temporary drop in blood pressure. - Rash: Mild skin erythema.

Serious or Rare Side Effects: - Agranulocytosis: Severe reduction in white blood cells. - Anaphylaxis: Immediate hypersensitivity reaction. - Stevens‑Johnson syndrome: Severe mucocutaneous eruption. - Hepatotoxicity: Liver enzyme elevation or injury. - Hemolytic anemia: Destruction of red blood cells.

When using Metamizol Basi, consider the following safety measures.

- Indication review: Confirm appropriate use for pain or fever. - Blood monitoring: Periodic complete blood counts to detect agranulocytosis. - Allergy assessment: Screen for known hypersensitivity to pyrazolones. - Pregnancy and lactation: Use only if benefits outweigh potential risks. - Renal/hepatic function: Adjust use in patients with organ impairment. - Store below 25°C: Keep in original container, protect from light and moisture.

Metamizol Basi can interact with several medication classes.

Major Interactions (Avoid): - Anticoagulants: Increased bleeding risk. - Other pyrazolone or NSAID agents: Heightened risk of agranulocytosis. - Immunosuppressants: Potential additive bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - ACE inhibitors: May enhance hypotensive effect. - Diuretics: Possible additive blood pressure lowering. - Corticosteroids: Monitor for enhanced immunosuppression.